Less than a tenth of individuals that would benefit from weight-loss injections including Wegovy are able to get them, caution the global health agency as it publishes its initial advice on the drugs.
Considering in excess of 1,000,000,000 people worldwide now living with obesity, it is urging increased and just availability to this class of drugs.
According to projections, in excess of 2,000,000,000 are projected to be obese by 2030 if no action is taken.
"Our new guidelines recognises that obesity is a chronic disease that can be treated with holistic and lifelong support," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are key obstacles to broad availability to the treatments that can aid individuals in losing substantial weight, says the agency.
GLP-1 Therapy Supply Crisis
Despite the present most optimistic case, the supply of these medications could only cover approximately 100 million people – fewer than 10% of the global need, per the health organization.
The recommendation encourages nations and manufacturers to expand availability, by approaches including voluntary licensing.
A patent on semaglutide – the primary ingredient of a leading brand – is scheduled to end in a number of nations in 2026.
The Way Obesity Jabs Work
GLP-1 drugs imitate a body's own hormone to slow digestion, reduce hunger and enhance satiety so people consume fewer calories.
Individuals typically begin shedding pounds within a few weeks of starting on the once-weekly jabs.
Research indicates patients may regain a significant portion within a year of halting the drug, because their usual hunger resume.
Being carrying excess weight raises your likelihood for developing health problems, including diabetes, cardiovascular issues, brain attack, and specific malignancies.
Obesity impacts individuals in every country and was linked to millions of deaths worldwide in 2024, as per the WHO.
